FUNI (Hypha Labs) Debt-to-Asset : 11.30 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Hypha Labs Debt-to-Asset?

Hypha Labs FUNI Debt-to-Asset is 11.30 as of Mar. 2026. The stock has 2 warning signs investors should review.

Hypha Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.30 Mil. Hypha Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $1.51 Mil. Hypha Labs's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2026 was $0.16 Mil. Hypha Labs's debt to asset for the quarter that ended in Mar. 2026 was 11.30.


Hypha Labs  (OTCPK:FUNI) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Hypha Labs Debt-to-Asset Related Terms


Hypha Labs Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Hypha Labs's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hypha Labs Debt-to-Asset Chart

Hypha Labs Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.25 1.75 1.63 2.31 4.02

Hypha Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.63 3.35 4.02 4.46 11.30

FUNI vs ISPC, BIAF, IVRO: Debt-to-Asset Comparison

For the Diagnostics & Research subindustry, Hypha Labs's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hypha Labs Debt-to-Asset vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Hypha Labs's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Hypha Labs's Debt-to-Asset falls into.



Hypha Labs Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Hypha Labs's Debt-to-Asset for the fiscal year that ended in Sep. 2025 is calculated as

Hypha Labs's Debt-to-Asset for the quarter that ended in Mar. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 11.30 mean?
Hypha Labs (FUNI) has a Debt-to-Asset of 11.30 as of Mar. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Hypha Labs and its competitors.
Is Hypha Labs' Debt-to-Asset too high?
Hypha Labs' current Debt-to-Asset is 11.30.
How does Hypha Labs' Debt-to-Asset compare to ISPC and BIAF?
Hypha Labs' Debt-to-Asset of 11.30 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Medical Diagnostics & Research company?
A good Debt-to-Asset depends on the Medical Diagnostics & Research industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Hypha Labs and its competitors. Hypha Labs's current Debt-to-Asset is 11.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hypha Labs stock overvalued right now?
Hypha Labs (FUNI) has a current Debt-to-Asset of 11.30. The current Debt-to-Asset is 11.30. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Hypha Labs (FUNI), the current Debt-to-Asset is 11.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hypha Labs Business Description

Address 5940 S. Rainbow Boulevard, Las Vegas, NV, USA, 89118
Hypha Labs Inc engaged in the research, development, and commercialization of the Hypha Micropearl accelerator, an in-home, web-based, computer-controlled bioreactor designed to accelerate the production of nutritionally beneficial mushrooms for human consumption. The Company's easy-to-use device, together with replaceable cartridges ordered through its exclusive app, safely and effectively produced enriched mycelium of functional mushrooms, or Micropearls, in eight days. These Micropearls contained active mushroom ingredients in a concentrated, easy-to-handle, tasteless, and odorless form that could be incorporated into various foods and beverages without altering flavor.